Summary
376.71 -0.25(-0.07%)05/16/2024
Argen X SE (ARGX)
Argen X SE (ARGX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.28 | 6.21 | 3.13 | 1.75 | -19.80 | -1.77 | 221.62 | 1,633.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 398.81 | |
| Open | 397.14 | |
| High | 398.81 | |
| Low | 393.02 | |
| Volume | 203,710 | |
| Change | 5.03 | |
| Change % | 1.28 | |
| Avg Volume (20 Days) | 228,062 | |
| Volume/Avg Volume (20 Days) Ratio | 0.89 | |
| 52 Week Range | 327.73 - 550.76 | |
| Price vs 52 Week High | -27.59% | |
| Price vs 52 Week Low | 21.69% | |
| Range | 0.42 | |
| Gap Up/Down | -0.21 | |
Fundamentals | ||
| Market Capitalization (Mln) | 22,401 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 360.12 | |
| Book Value | 57.4320 | |
| Earnings Per Share | -7.2410 | |
| EPS Estimate Current Quarter | -4.4200 | |
| EPS Estimate Next Quarter | -4.8400 | |
| EPS Estimate Current Year | -8.5300 | |
| EPS Estimate Next Year | -19.3300 | |
| Diluted EPS (TTM) | -7.2410 | |
| Revenues | ||
| Profit Marging | -0.7305 | |
| Operating Marging (TTM) | -0.5376 | |
| Return on asset (TTM) | -0.0436 | |
| Return on equity (TTM) | -0.1414 | |
| Revenue TTM | 510,079,840 | |
| Revenue per share TTM | 9.9130 | |
| Quarterly Revenue Growth (YOY) | -0.4650 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -270,945,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.1987 | |
| Revenue Enterprise Value | 25.5590 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 51,515,000 | |
| Shares Float | 46,563,591 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 55.70 | |
05/09 16:39 EST - seekingalpha.com
argenx SE (ARGX) Q1 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Rajan Sharma - Goldman Sachs Derek Archila - Wells Fargo James Gordon - JPMorgan Akash Tewari - Jefferies Yaron Werber - TD Cowen Brian Conley - Leerink Partners Alex Thompson - Stifel Xian Deng - UBS Vikram Purohit - Morgan Stanley Danielle Brill - Raymond James Samantha Semenkow - Citi Gavin Clark-Gartner - Evercore ISI Yatin Suneja - Guggenheim Victor Floch - BNP Paribas Joel Beatty - Baird Manos Mastorakis - Deutsche Bank Matt Phipps - William Blair Douglas Tsao - H. C. Wainwright Operator Good morning.
argenx SE (ARGX) Q1 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Rajan Sharma - Goldman Sachs Derek Archila - Wells Fargo James Gordon - JPMorgan Akash Tewari - Jefferies Yaron Werber - TD Cowen Brian Conley - Leerink Partners Alex Thompson - Stifel Xian Deng - UBS Vikram Purohit - Morgan Stanley Danielle Brill - Raymond James Samantha Semenkow - Citi Gavin Clark-Gartner - Evercore ISI Yatin Suneja - Guggenheim Victor Floch - BNP Paribas Joel Beatty - Baird Manos Mastorakis - Deutsche Bank Matt Phipps - William Blair Douglas Tsao - H. C. Wainwright Operator Good morning.
05/09 01:00 EST - globenewswire.com
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2024 results and provided a business update. “The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2024 results and provided a business update. “The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
05/08 12:00 EST - zacks.com
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
05/07 17:30 EST - globenewswire.com
argenx announces results of Annual General Meeting of Shareholders
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy).
argenx announces results of Annual General Meeting of Shareholders
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy).
05/07 04:02 EST - seekingalpha.com
argenx: Innovation Over Losses In Autoimmune Arena
argenx stock has decreased by 22% since the last evaluation, reflecting operational challenges and market conditions. The company is facing competition in the clinic, particularly from Immunovant's IMVT-1402 and Johnson & Johnson's nipocalimab. Despite high R&D and SG&A expenses leading to losses, argenx reported substantial revenue growth and maintains a strong cash position.
argenx: Innovation Over Losses In Autoimmune Arena
argenx stock has decreased by 22% since the last evaluation, reflecting operational challenges and market conditions. The company is facing competition in the clinic, particularly from Immunovant's IMVT-1402 and Johnson & Johnson's nipocalimab. Despite high R&D and SG&A expenses leading to losses, argenx reported substantial revenue growth and maintains a strong cash position.
05/07 01:00 EST - globenewswire.com
argenx to Present at BofA Securities 2024 Health Care Conference
May 7, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV.
argenx to Present at BofA Securities 2024 Health Care Conference
May 7, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV.
05/02 01:00 EST - globenewswire.com
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update.
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update.
04/23 14:21 EST - zacks.com
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
04/16 01:00 EST - globenewswire.com
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years
03/27 02:00 EST - globenewswire.com
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease (SjD), following the analysis of topline data from the Phase 2 RHO study. Detailed results will be presented at a future medical meeting.
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease (SjD), following the analysis of topline data from the Phase 2 RHO study. Detailed results will be presented at a future medical meeting.
03/26 16:00 EST - globenewswire.com
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 7, 2024 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 7, 2024 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
03/26 02:00 EST - globenewswire.com
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)
03/22 11:31 EST - zacks.com
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
03/22 08:51 EST - zacks.com
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
03/21 09:25 EST - investors.com
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.
03/07 16:01 EST - globenewswire.com
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART® and VYVGART® Hytrulo in gMG patients March 7, 2024, 10:01 pm CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that eight abstracts, including two oral presentations, featuring clinical trial and real-world data for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in rare autoimmune diseases will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, CO from April 13-18, 2024. “We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D.
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART® and VYVGART® Hytrulo in gMG patients March 7, 2024, 10:01 pm CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that eight abstracts, including two oral presentations, featuring clinical trial and real-world data for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in rare autoimmune diseases will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, CO from April 13-18, 2024. “We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D.
02/29 13:26 EST - seekingalpha.com
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
02/29 01:00 EST - globenewswire.com
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024 Management to host conference call today at 2:30 pm CET (8:30 am ET) February 29, 2024, 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2023 and provided a fourth quarter business update. “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024 Management to host conference call today at 2:30 pm CET (8:30 am ET) February 29, 2024, 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2023 and provided a fourth quarter business update. “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
02/26 01:00 EST - globenewswire.com
argenx to Present at Upcoming Investor Conferences
February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March:
argenx to Present at Upcoming Investor Conferences
February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March: